Doug Campos-Outcalt, MD, Medical Director, Mercy Care Plan, Phoenix, AZ
TIPS ABOUT VACCINES FOR OLDER ADULTS
Vaccines are among the most successful public health interventions, saving millions of lives and preventing millions of disabilities. While most vaccines are targeted at children and young adults, there are five recommended for routine use in adults aged 65 and older: influenza vaccine, two types of pneumococcal vaccine, herpes zoster vaccine, and a vaccine against tetanus and diphtheria. The latter includes the addition of pertussis protection in a vaccine (given one time) that combines tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap). This issue of Elder Care will discuss these five vaccines.
Other vaccines are also available for older adults, (Table 1) but will not be reviewed in this Elder Care. They include vaccines for older adults with particular health risks (e.g., vaccines against hepatitis A and B and meningococcus, and vaccines for individuals who travel outside of the US). Information on these and other vaccines is available from the Centers for Disease Control and Prevention (CDC).
While the highest rate of influenza infection is among children, the highest rate of serious illness and death usually occurs among older adults. Indeed, influenza causes an average of 36,000 deaths in the US each year, most of which occur in older adults. Thus, the CDC's Advisory Committee on Immunization Practices (ACIP) recommends that all older adults receive annual influenza vaccination.
There are six influenza vaccines available for older adults in the US. They include the 3-valent inactivated influenza vaccine (IIV3), 4-valent inactivated influenza vaccine (IIV4), 3-valent high-dose influenza vaccine (IIV3-HD), and 4-valent standard dose vaccine (IIV4), 3-valent high-dose vaccine (IIV3-HD), 4-valent cell-culture vaccine (ccIIV4), 3-valent adjuvanted standard dose vaccine (IIV3-A), and 4-valent recombinant vaccine (RIV4).
The high-dose vaccine (IIV3-HD) and 3-valent adjuvanted standard dose vaccine (IIV3-A) are specifically licensed only for adults aged 65 and older. The first contains a higher dose of antigen compared to the other influenza vaccines, and the second contains an adjuvant to stimulate the immune system. The hope is that it will lead to a stronger immune response in older adults which, in turn, will translate into less influenza-related morbidity and mortality. The Advisory Committee on Immunization currently does not state a preference for which of the six vaccines should be given to older adults.
Note that a history of egg allergy is no longer an automatic contraindication to influenza vaccine. Individuals who have experienced urticaria following exposure to egg should receive influenza vaccine but only from a clinician familiar with treatment of severe allergic reactions. For people who have a history of anaphylaxis to eggs, there are now two influenza vaccines that are not prepared in eggs (ccIIV4 and RIV4), but only RIV4 is considered egg-free.
Table 1. Vaccines Recommended for Older Adults
Routine Vaccines (for all adults)
|Influenza||1 dose annually|
|Pneumococcal (PCV13)||1 dose (at age 65)|
|Pneumococcal (PPSV23)||1 dose (≥12 mo after PCV 13)|
|Tetanus, diphtheria pertussis||Td every 10 years. (Substitute 1-time dose of Tdap for one Td booster)*|
|Zoster||2 doses (at age 50)|
|Vaccines for Special Situations (based on medical, occupational, lifestyle, or other indications)|
|Hepatitis A||2 doses|
|Hepatitis B||3 doses, or two doses depending on the product|
|Measles, mumps, rubella||1-2 doses|
|Meningococcus||1 or more doses|
|Source: CDC Vaccines|
There are now two pneumococcal vaccines recommended for use in older adults - the older polysaccharide PPSV23 vaccine (Pneumovax) and the new conjugate PCV13 vaccine (Prevnar). Current recommendations are to administer PCV13 at age 65 followed at least 12 months later by PPSV23.
If an individual already received PPSV23 at or after age 65, PCV13 should be given, but not until at least one year has elapsed since PPSV23 was given. If an individual received PPSV23 before age 65 because of a high-risk condition, PCV13 should be given at age 65 (but at least one year after PPSV23), followed by another dose of PPSV23 at least 12 months after PCV13 and 5 years since the PPSV23.
Herpes Zoster Vaccine
In 2017, the US Food and Drug Administration approved a new vaccine against shingles (Herpes Zoster), an adjuvanted recombinant zoster vaccine (RZV), Shingrix. It is administered in 2 doses at least 2 months apart and provides much better and longer-acting protection than does the older live attenuated virus (ZVL) vaccine, Zostavax. The RZV is now recommended for all those age 50 and older (including those previously vaccinated with ZVL), and it is the preferred option for those wanting protection against shingles.
Td or Tdap Vaccines
All adults should receive a booster tetanus and diphtheria vaccine at least every 10 years, after a three-dose primary series (which is usually received as an infant or child). A new product that includes tetanus and diphtheria toxoid plus acellular pertussis antigen (Tdap) is available to provide adults with protection against pertussis in addition to tetanus and diphtheria. This vaccine not only provides pertussis protection for the adult; it can prevent an adult from passing pertussis to an infant. ACIP now recommends that all adults receive a dose of Tdap as one of their every-10-year immunizations, if they have not already done so. However, if an older adult will be in close contact with a newborn infant, Tdap should be administered without waiting for the 10-year period.
The payment system for adult vaccines is confusing because, as shown in Table 2, some vaccines are covered through Medicare Part B (physician office charges), others are covered through Part D (drug coverage), and in special situations they are covered by Parts B and D. This creates a problem for medical practices in that they may have difficulty arranging reimbursement through part D. As a result, some practices do not provide zoster vaccine or tetanus-diphtheria (or Tdap) for Medicare patients. Other locations at which to receive these vaccines include pharmacies, hospitals, and public health departments.
|Table 2. Medicare Coverage for Older Adults' Vaccines|
|Vaccine||Part B||Part D|
Family and Intergenerational Aspects of Vaccines
An often-overlooked benefit of vaccines is the protection afforded against intergenerational transmission of infection. For instance, influenza in children above the age of 4 years is usually not serious, but immunizing them against influenza can prevent transmission of the disease to grandparents who are at much higher risk of complications. Conversely, immunization of older adults against pertussis prevents them from infecting infants, who have much more severe reactions to this infection. Vaccines should thus be seen as both a personal and a family prevention strategy.
References and Resources
- CDC. Vaccine Information for Adults.
- Dooling KL, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR 2018; 67(3): 103-108.
- Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2018-19 Influenza Season. MMWR Recommendations and Reports 2018 ; 67(3):1-20.